Surv Biopharma develops a drug discovery platform that facilitates research and development of veterinary drugs and pharmaceutical products.
Surv Biopharma has raised $9.7M in total funding. The most recent round was Series B. The last funding was announced in November 2025.
Surv Biopharma's investors include Keio Innovation Initiative, Nippon Venture Capital, DCI Partners, Higin Capital, QB Capital.
Surv Biopharma is headquartered in Kagoshima, Japan.
Surv Biopharma develops a drug discovery platform that facilitates research and development of veterinary drugs and pharmaceutical products.
Surv Biopharma is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Surv Biopharma — Funding & Investors." VCBacked, November 11, 2025, https://www.vcbacked.co/company/surv-biopharma. Accessed September 15, 2026.
VCBacked. (2025). Surv Biopharma — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/surv-biopharma
{{cite web |title=Surv Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/surv-biopharma |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated